Sema-Pep 5mg

Sema-Pep Dragon Pharma

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of medication used in the management of type 2 diabetes. According to the medical literature, it enhances glucose-dependent insulin secretion and decreases glucagon secretion, thereby improving glycemic control.

References

Research published in reputable journals such as The New England Journal of Medicine has demonstrated its efficacy in reducing HbA1c levels and promoting weight loss in patients with type 2 diabetes. Furthermore, semaglutide has been shown to be well-tolerated with a favorable safety profile, as outlined in studies like the STEP-1 trial. It is administered subcutaneously, typically once weekly, and its prolonged duration of action is attributed to an albumin-binding property that extends its half-life. The medication is also under investigation for its potential in the treatment of obesity and other metabolic disorders, with promising results emerging from clinical trials. Notable texts such as "Diabetes: Etiology, Pathophysiology, Diagnosis, and Treatment" by Alan R. Rubin and "Goodman & Gilman's The Pharmacological Basis of Therapeutics" by Laurence L. Brunton and others provide comprehensive details on the pharmacology and therapeutic use of semaglutide and other GLP-1 receptor agonists.